A sodium-glucose cotransporter 2 (SGLT2) inhibitor with proven benefit for the specific comorbidity is recommended as part of the glucose-lowering regimen for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high risk, established kidney disease, or heart failure. Data from several cardiovascular outcomes trials have provided evidence of cardiovascular benefits from the use of certain SGLT2 inhibitors and glucagon-like peptide 1 receptor agonists. Similarly, some of these drugs have also been recently shown to have beneficial renal effects as well. Therefore, it is important to think of these comorbidities when making treatment decisions.
So far, there has been no evidence of similar cardiovascular or renal benefits of lowering glucose using older therapies indicated for patients with type 2 diabetes, such as metformin, sulfonylureas, thiazolidinediones, or insulin, or for the newer dipeptidyl peptidase 4 inhibitors.
Learn more about cardiovascular risk management in type 2 diabetes.
Editor's Recommendations
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Fast Five Quiz: Glycemic Control in Type 2 Diabetes - Medscape - Jan 12, 2022.
Comments